IRulya Therapeutics Inc. Common Stock
IRLA
41 hedge funds and large institutions have $4.68M invested in IRulya Therapeutics Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 5 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
2.51% less ownership
Funds ownership: 16.96% → 14.46% (-2.5%)
7% less funds holding
Funds holding: 44 → 41 (-3)
39% less capital invested
Capital invested by funds: $7.71M → $4.68M (-$3.03M)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
+$309K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$75K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$66.3K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$59.8K |
| 5 |
BlackRock
New York
|
+$20.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.31M |
| 2 |
SI
Scharf Investments
Los Gatos,
California
|
-$96.5K |
| 3 |
Renaissance Technologies
New York
|
-$32.7K |
| 4 |
IC
IEQ Capital
Foster City,
California
|
-$23.9K |
| 5 |
Millennium Management
New York
|
-$15.4K |
IRLA Hedge Fund Activity: Q2 2024 in Review
41 of the 6,939 institutional investors tracked by Wall St. Rank reported a position in IRulya Therapeutics Inc. Common Stock (IRLA) for Q2 2024, worth a combined $4.68M — down 39% from $7.71M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IRLA and 2 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 10 added.
The largest buyer was HighTower Advisors, opening a new position worth an estimated $309K. The largest seller was Tang Capital Management, cutting an estimated $1.31M.
- 41 institutional investors held IRulya Therapeutics Inc. Common Stock (IRLA) as of Q2 2024, down from 44 in Q1 2024.
- Funds reported $4.68M of IRulya Therapeutics Inc. Common Stock stock for Q2 2024, down 39% quarter-over-quarter.
- 2 funds opened new IRulya Therapeutics Inc. Common Stock positions in Q2 2024 and 5 closed out, a net change of -3 holders.
- The largest IRulya Therapeutics Inc. Common Stock buyer in Q2 2024 was HighTower Advisors, an estimated $309K added.
- The largest IRulya Therapeutics Inc. Common Stock seller in Q2 2024 was Tang Capital Management, an estimated $1.31M sold.
Based on aggregated 13F filings for Q2 2024.